indicates that both authors contributed equally to this paper.
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs
Version of Record online: 15 OCT 2013
© 2013 The Authors. BJU International © 2013 BJU International
Special Issue: Urological Society of Australia and New Zealand Supplement
Volume 112, Issue Supplement S2, pages 36–43, November 2013
How to Cite
Ta, A. D., Bolton, D. M., Dimech, M. K., White, V., Davis, I. D., Coory, M., Millar, J. and Giles, G. (2013), Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU International, 112: 36–43. doi: 10.1111/bju.12204
- Issue online: 15 OCT 2013
- Version of Record online: 15 OCT 2013
- Translational Cancer Research Funding
- Victorian Cancer Agency. Grant Number: EOI09_36
- National Health and Medical Research Council (NHMRC) Practitioner Fellowship. Grant Number: 487907
- renal cell carcinoma (RCC);
- cancer registry;
- chronic kidney disease (CKD)
- To describe the contemporary patterns of care for renal cell carcinoma (RCC) using a whole of population series from Victoria.
Patients and methods
- Retrospective review of medical records of all patients diagnosed and treated for RCC in Victoria in 2009.
- Patients were identified via the State-wide Victorian Cancer Registry.
- Patient demographic characteristics, symptoms, stage, and first-line treatment were assessed.
- Associations between case residential location (metropolitan or rural) and treatment were examined using multivariate logistic regression after adjusting for age, sex, socioeconomic status, treatment in private or public hospital and comorbidity.
- Data were obtained for 499 of 577 eligible patients.
- In all, 413 patients (83%) underwent surgery.
- Laparoscopic radical nephrectomy (RN) was the most common procedure for Stage I pT1a/pT1b tumours (51.2%); partial nephrectomy (PN) was performed for 27% of Stage I RCC
- In multivariate analysis, regional patients were less likely to receive PN (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.18–0.85) for Stage I RCC, and less likely to receive systemic therapy for Stage IV RCC (OR 0.06, 95% CI 0.01–0.41).
- Multidisciplinary team meetings were recorded for only 25% of patients and 3% were enrolled in a clinical trial.
- Most contemporary patients diagnosed with RCC are still treated with RN, including those with smaller tumours amenable to PN.
- This may impact future outcomes, including increased risk of chronic kidney disease and its potential financial healthcare burden.
- Patterns of treatment also appear to differ between metropolitan and regional populations.